Industry Laments UK Change To SPC Waiver Approach
Manufacturing Of Products Under SPC Only Allowed For Non-EU Markets
Changes to how the UK plans to implement the SPC manufacturing waiver after it separates itself fully from the EU following the current Brexit transition period have been criticized by the generics industry, while originators have welcomed the move.
You may also be interested in...
As the generics and biosimilars industries prepare for the European SPC manufacturing waiver to come into effect on 1 July, Generics Bulletin traces the history of the mechanism from early industry lobbying efforts to its ultimate entry into force.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.